Spirocyclic Amide Derivatives Dual Receptor Agonist Antagonist
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary disorders like COPD and asthma often require co-administration of muscarinic-receptor antagonists and β-adrenoceptor agonists, which can be cumbersome and may not offer optimal efficacy and side-effect profiles.
Innovation Solution
Development of spirocyclic amide derivatives that act as dual adrenergic β receptor agonists and muscarinic receptor antagonists, providing a single molecule with combined bronchodilator effects to improve lung function and patient compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If co-administration of muscarinic-receptor antagonists and β-adrenoceptor agonists is used, then bronchodilator efficacy is improved, but treatment complexity and patient compliance deteriorate
Solution Approach 1:
The patent merges two separate therapeutic agents (muscarinic-receptor antagonist and β-adrenoceptor agonist) into a single dual-action molecule. This is achieved by designing a spirocyclic amide derivative structure that contains both pharmacophoric elements: a muscarinic antagonist moiety (typically a quaternary ammonium group) and a β-adrenergic agonist moiety (catecholamine structure with specific substituents), connected through a spirocyclic linker. The single molecule simultaneously binds to both muscarinic receptors and β-adrenoceptors, providing combined bronchodilator effects while simplifying administration to once-daily inhalation.
Solution Approach 2:
The invention creates a universal therapeutic agent that performs multiple functions: it acts as both a muscarinic-receptor antagonist and a β-adrenoceptor agonist within the same molecule. This multi-functionality allows the single compound to address multiple pathophysiological mechanisms in COPD and asthma (vagally-mediated bronchoconstriction and β-adrenergic tone) simultaneously, replacing the need for two separate medications while maintaining or enhancing clinical efficacy.
2Adaptability or versatility
If co-administration of two separate compounds is used, then therapeutic coverage is improved, but formulation complexity deteriorates
Solution Approach 1:
The patent combines two distinct therapeutic compounds into a single molecular entity through chemical synthesis. The dual-action molecule is formulated as a single substance for inhalation, eliminating the need for complex multi-component formulations, combination device assemblies, or coordinated delivery mechanisms required for co-administration of two separate medications.
3Ease of operation
If single agent therapy is used, then ease of use is improved, but therapeutic efficacy deteriorates
Solution Approach 1:
The single agent designed in this patent achieves multi-functionality by incorporating both muscarinic antagonist and β-adrenergic agonist activities within one molecule. This allows the compound to deliver broad therapeutic coverage (addressing multiple bronchoconstriction mechanisms) while maintaining simplicity of use (single inhalation device, once-daily dosing), thereby resolving the trade-off between ease of use and therapeutic efficacy.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Spirocyclic amide derivatives of formula (I) wherein ArCH2CH2NH- represents a β-adrenoceptor binding group, processes for their preparation, pharmaceutical compositions containing them, a process for preparing such pharmaceutical compositions, their use in therapy, and intermediates for use in their preparation.